Objective: To examine associations between a diabetes pay-for-performance (P4P) program in Taiwan and all-cause of mortality and competing causes of death in cancer survivors with type 2 diabetes. Design: A longitudinal observational intervention and comparison group study design. Setting and participants: Cancer survivors with type 2 diabetes who enrolled in the P4P program compared with survivors who did not participate (non-P4P) under the Taiwan National Health Insurance program. Intervention(s): A nationwide diabetes P4P program. Main outcome measures: The main outcome was a comparison of all-cause, diabetes-related and cancer mortality in P4P and non-P4P patients during a 5-year follow-up period. Total person-years and mortality rates per 1000 person-years for causes of death were calculated. Multivariate Cox proportional hazard models and competing risk regression were used in the analysis. Results: Overall, our results indicate that P4P cancer survivors had lower risk of all-cause mortality and diabetes-related mortality than non-P4P survivors. Specifically, the hazard ratio (95% confidence interval) was 0.581 (0.447-0.756) for all-cause mortality; SHRs were 0.451 (0.266-0.765) for diabetes-related mortality and 0.791 (0.558-1.121) for cancer mortality. Conclusions: Our empirical findings provide evidence of potential benefits of diabetes P4P programs in reducing risks of deaths due to diabetes or cardiovascular diseases among cancer survivors, compared with survivors who did not enroll in the P4P program. In consideration of recommended care for long-term survival, the diabetes P4P program can serve as a care model for cancer survivors for reducing mortality due to diabetes or cardiovascular diseases.
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Background
The population of cancer survivors is growing worldwide in accordance with an ageing population and advances in cancer prevention, early detection and treatment [1, 2] . In the United States, the number of survivors increased from 3 million in 1971 to more than 15.5 million in 2016, and is projected to reach more than 20.3 million in 2026 [1] . A current estimate showed that 62% of all cancer survivors were aged 65 years or older, and 44-64% of elderly survivors had at least one comorbid condition [1, 3] . In addition to cancer, multiple comorbid conditions, such as diabetes, are life threatening for many survivors [4] . Diabetes mellitus (DM) is consistently the most common comorbid conditions for survivors of all cancer types, ranging from 22% to 29% with little variation between age groups [1, 3, 5] . Patients with both cancer and diabetes have worse patientreported health outcomes than patients with either disease [5] . Diabetes is associated with a 30-40% increased mortality risk among cancer patients [6] .
Although the importance of optimizing care delivery to cancer survivors was recognized in the 2005 Institute of Medicine report, 'From Cancer Patient to Cancer Survivor: Lost in Transition' [2] , specific guidance for health management and prevention of comorbid conditions has not been established [7, 8] . Currently available evidence for interventions primarily focuses on treating index cancers, given research findings from clinical trials in which study selection criteria may exclude patients with comorbid conditions to avoid potential interaction effects or confounding of results [9] . Thus, knowledge is lacking regarding what interventions might mitigate the effects or risks of non-cancer diseases on health outcomes for cancer survivors with comorbid conditions [9] .
Pay-for-performance (P4P) or value-based purchasing programs have been embraced by many developed nations as a strategic tool to stimulate delivery of long-term, multidisciplinary care, and to invest less money on incentives while efficiently improving health care quality [10] [11] [12] . For example, the United Kingdom's Quality and Outcome Framework and Australia's P4P programs pay extra bonuses to reward improvements in care for diabetes patients [11, 13] . In Taiwan, a diabetes P4P program was implemented nationwide by Taiwan's National Health Insurance Administration (NHIA) at the end of 2001 in an effort to provide comprehensive diabetes care by following the American Diabetes Association's clinical practice guidelines [14] . However, the effectiveness of the P4P program has been mixed [15] . Recent studies suggest that comprehensive care through diabetes P4P programs may enhance quality of care and prevent or delay vascular complications or reduce risks of all-cause mortality in the general population with diabetes [14, 16, 17] . Nevertheless, to the best of our knowledge, no empirical studies have assessed whether comprehensive diabetes care through a P4P program has any effect on health outcomes, particularly for cancer survivors with comorbid diabetes.
This study aimed to examine the effects on mortality of comprehensive diabetes care provided through a nationwide diabetes P4P program among cancer survivors with diabetes in Taiwan. Specifically, we conducted an observational intervention and comparison cohort study using data from three population-based databases in Taiwan to examine the extent to which the P4P program and other risk factors were associated with all-cause mortality and competing causes of deaths (diabetes-related and cancer) in cancer survivors with type 2 diabetes who enrolled in the P4P program versus a group of survivors who did not participate in the P4P program.
Methods
The P4P program A diabetes P4P program was implemented by Taiwan's NHIA in 2001 to improve the quality of health care for diabetes patients. It consists of several important features. First, only physicians who specialize in metabolic disorders or endocrinology or who attended a training program for diabetes care are eligible to participate in and voluntarily enroll patients into this special P4P for diabetes care. Second, medical care teams are expected to work as coordinated physician-led multidisciplinary teams adhering to the American Diabetes Association's clinical guidelines. Third, in addition to regular and usual care, P4P patients received extra comprehensive care, including medical history assessment, physical examination, laboratory evaluation, management plan evaluation, and self-management and health education. Fourth, participating P4P physicians receive extra incentive payments in addition to regular physician fees depending on incentive targets for improving processes (e.g. documented HbA1c or LDL tests) and intermediate outcomes (e.g. higher percentages of patients with controlled HbA1c or LDL) [10, 14] .
Study design and data source
We conducted a longitudinal observational case and control cohort study using three population-based databases in Taiwan: (i) a 2-million-sample longitudinal health and welfare database from 2000 to 2010, a nationally representative random sample of NHIAenrolled beneficiaries in 2005, from which we obtained information on patient comorbid conditions, health provider characteristics and billing variables to identify enrollment in the P4P program; (ii) the death registry database, which provides accurate death dates and causes of death information; (iii) the national cancer registry, from which we obtained accurate cancer diagnosis data tracking from 1979 to 2010. Three databases were linked with encrypted patient identifiers and all data analysis was completed in the Health and Welfare Data Science Center, the Ministry of Health and Welfare in Taiwan in 2015-2016. This study was approved by the Institutional Review Board at the authors' associated research institution.
Study population
Using nationwide NHIA claims data, we included patients with a primary diabetes diagnosis code (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 250.xx) for at least two outpatient visits (OP) or at least one inpatient hospitalization each year during the patient identification period, 2002-2005. We identified newly enrolled P4P patients using billing code 'P14x' (internal code) in the claims during the patient identification period, and defined the index date as the date of first enrollment. We identified non-P4P diabetes patients for the comparison group, who were not found to be enrolled in the P4P program during the patient identification or follow-up periods. As non-P4P patients lacked specific P4P enrollment index dates, we randomly assigned index dates based on the dynamic frequency distribution of time exposure to the P4P intervention from the P4P group [18] . Using the cancer registry database, we identified diabetic cancer survivors who were ever diagnosed with any invasive cancer at least 1 year before the index date, and excluded those with any cancer diagnosis within 1 year before the index date [19] . We excluded patients with type 1 diabetes (ICD-9-CM codes 250.x1 or 250.x3) because they made up less than 1% of all newly enrolled diabetes patients, and patients aged younger than 18 years on the index date. Appendix Figure 1 provides detailed information about study inclusion and exclusion criteria.
Variable definitions
Outcomes of interest The major outcome of interest was a comparison of all-cause, diabetes-related and cancer mortality in P4P and non-P4P patients during the 5-year follow-up period. Diabetes-related and cancer deaths were identified from causes of death based on ICD-9-CM and International Classification of Diseases, Tenth Revision (ICD-10) codes in the national death registry data (Appendix Table 1 ). We defined diabetes-related death by the major risks of complications and prognoses of diabetes that may cause death, including DM, macrovascular complications (e.g. cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases) and microvascular complications (e.g. nephropathy and neuropathy disease) [20] . To compare groups, we followed each P4P and non-P4P patient for 5 years. Patients who discontinued the insurance program or died were censored. We calculated total person-years for each patient and mortality rates per 1000 person-years for causes of death.
Covariate assessment
Several baseline characteristics that may affect outcomes were included as control variables. Patient covariates included age, sex, residential setting (urban or rural), the Diabetes Complication Severity Index (DCSI) [20] and the Chronic Illness With Complexity (CIC) index within 1 year before the index date [21] . The DCSI and CIC indexes are frequently used in studies [20] [21] [22] . The DCSI includes seven categories of complications by ICD-9-CM code: cardiovascular complications, nephropathy, retinopathy, peripheral vascular disease, stroke, neuropathy and metabolic disorders. The CIC index includes non-diabetes physical illness complexity (cancers and gastrointestinal, musculoskeletal and pulmonary diseases), diabetes-related complexity and mental illness/substance abuse complexity. We excluded cancer and diabetes-related complexity when constructing the CIC index to avoid duplicating comorbidity identified by the DCSI [22] .
Additionally, because cancer survivors' care trajectories may differ [2] , we controlled for baseline density of diabetes and cancer care and time since cancer diagnosis. Baseline density of diabetes or cancer care was calculated as total OP related to diabetes (ICD-9-CM diagnosis code 250) or cancer (ICD-9-CM diagnosis codes 140-208) divided by total OP within 1 year before the index date, and categorized as low or high based on the threshold of 75th percentile of value. Time since cancer diagnosis was calculated as the difference in years between the last invasive cancer diagnosis date and the index date, using data from the cancer registry.
As the P4P program requires staff to work as a team and cost structures may differ in different health institutions, provider characteristics were included to identify the resources and capacities of individual health care institutions; characteristics included accreditation levels (medical center, regional hospital, local hospital or clinic) and geographic locations (Taipei, northern, central, southern, Kao-Ping or eastern area).
Statistical analysis
To avoid potential confounding by selection bias and confounding factors, we used a propensity score matching (PSM) approach to determine adequate comparison groups. Using a logistic regression model, we created propensity scores that predicted the probability of enrollment into the diabetes P4P program among cancer survivors. The PSM caliper matching method with 1-to-2 match was used to match intervention group with comparison group members based on propensity score [23, 24] . This approach essentially finds the nearest distance of probabilities regarding the estimated propensity score to determine the best matches with the smallest standard deviations between case and control groups. If more than one potential control group member has the same propensity score as a case, the algorithm randomly selects one for inclusion in the control group [23, 24] . Covariates included demographic characteristics (age, sex, residential setting), comorbid conditions (DCSI, CIC), baseline density of diabetes and cancer care, time since cancer diagnosis and health institution characteristics (accreditation level and geographic locations).
In addition, we used multivariate Cox proportional hazard models to estimate the likelihood of all-cause mortality comparing matched P4P and non-P4P patients. To account for competing causes of death between cancer and diabetes, we conducted a sensitivity analysis using competing risk regression models, and report the sub-distribution hazard ratios (SHRs) [25] . Potential confounding variables as presented in Table 1 were controlled for. Patients were clustered within matched pairs and health care institutions to control for unequal error variances across matched pairs and health care providers. Adjusted cumulative hazard curves for all-cause mortality and adjusted cumulative incidence curves for diabetes or cancer mortality were created. All statistical operations were performed using SAS version 9.4 (SAS institute, Cary, NC) and Stata version SE 13. A P value <0.05 was considered significant. Table 1 summarizes patient and health care provider baseline characteristics for the P4P and non-P4P cohorts (before and after matching). Before matching, we included 410 P4P and 2576 non-P4P cancer survivors with diabetes. P4P patients were 35.61% male with mean age 64.79 years, mean DCSI 1.08, mean CIC 1.74, mean density of diabetes care 0.38, mean density of cancer care 0.18 and mean time since cancer diagnosis 7.09 years; a high proportion were diagnosed with colorectal, breast or cervical cancers. Non-P4P patients were 43.05% male with mean age 67.42 years, mean DCSI 1.06, mean CIC 1.84, mean density of diabetes care 0.29, mean density of cancer care 0.21 and mean time since cancer diagnosis 6.59 years. Significant differences were found between the prematched intervention and comparison groups (P < 0.001) with respect to several characteristics assessed. After PSM 1-to-2 matching, all baseline characteristics between the two matched groups were found to be comparable. Table 2 compares numbers of total person-years and mortality rates per 1000 person-years for causes of death between P4P and non-P4P patients. Table 3 presents the adjusted hazard ratios from multivariate Cox proportional hazard models and adjusted SHRs from competing 
Results
1 Descriptive results of patient and health care institution characteristics among P4P and non-P4P cancer survivors with diabetes
Variables
Before PSM matching After PSM matching Regarding other confounding factors, men, older patients, patients with more severe comorbidity and patients with higher baseline density of cancer care tended to have higher risk of all-cause mortality; older patients and patients with more severe comorbidity had higher risk of diabetes-related mortality; and men, patients with more severe comorbidity and patients with higher baseline density of cancer care had higher risk of cancer mortality. Fig. 1 presents adjusted cumulative hazard curves for all-cause mortality and adjusted cumulative incidence curves for diabetes-related and cancer mortality comparing P4P and non-P4P cancer survivors with diabetes.
Discussion
Cancer survivors are at risk for progressive diseases and other comorbid conditions (e.g. diabetes), functional decline and premature death [3, 8, 19, 26] . From the perspective of cancer as a chronic illness, development of a comprehensive care program, consisting of clinical treatment and lifestyle health practices, becomes more important for long-term cancer survivors [7, 19] . However, evidence of the effectiveness of providing comprehensive care for cancer survivors with comorbid conditions is lacking [7, 9] . We evaluated whether comprehensive diabetes care through a diabetes P4P program in Taiwan effectively decreased all-cause and specific-cause mortality comparing cancer survivors with type 2 diabetes who did and did not enroll in the program. Overall, our findings indicated no difference in risk of cancer mortality for diabetic survivors enrolled in a diabetes P4P program, but significantly lower risks of all-cause and diabetesrelated mortality, compared with non-P4P survivors.
One study showed that cancer patients died of non-cancer causes at a relative hazard ratio 1.37 higher than persons without cancer, and almost half of the deaths were from cardiovascular diseases [26, 27] . Therefore, optimizing the delivery of care and providing specific guidance in health management and prevention to cancer survivors with comorbid conditions is important [2, 4] . A previous study found that general population diabetes patients in the diabetes P4P program had lower risk of cardiovascular events and all-cause mortality [17] . However, none of these studies focused on the effectiveness of the 
Geographical location (n, %) Cancer type categories were not mutually exclusive. This set of cancer type variables was not included in the PSM and multivariate analysis. Although the diabetes P4P program is not specifically designed for cancer survivors, several key features provide comprehensive disease management for diabetic survivors and might explain the study findings. First, the diabetes P4P program in Taiwan requires participating health care providers to adhere to the American Diabetes Association's clinical practice guidelines for patients with diabetes. The guidelines are consistent with the nutrition and physical activity guidelines for cancer survivors suggested by the American Cancer Society, including specific treatment recommendations for diabetes and common diabetes-related diseases (e.g. cardiovascular diseases), and recommendations for psychosocial and social assessment and care, preventive care (immunization, vaccinations, screening), lifestyle changes, diet, physical activities and obesity management [9, 28] . Second, P4P patients received significantly more intensive and frequent follow-up than non-P4P patients [22] . Thus, P4P cancer survivors may have additional opportunity to receive care for their chronic illness and decrease risks of diabetes-or cardiovascular-specific death [29] .
This study has several limitations. First, given the limitation of our study data periods in administrative claims, we were unable to track the number of years since diabetes was diagnosed or to identify whether patients were newly diagnosed. However, we were able to track the time since cancer diagnosis through the cancer registry dataset, 1979-2010. Second, ICD-9-CM codes for claims and cause of death on death certificates may be inaccurate. Third, unobservable confounders for individual patients (e.g. lifestyle, prescription adherence, illness experience, smoking status, body weight or quality of life during serious illness) were not available in the secondary claim database. Fourth, according to program regulations, physicians who specialize in metabolic disorders or endocrinology or who attended a training program for diabetes care are eligible to participate in and voluntarily enroll patients into this special P4P for diabetes care. Patients of P4P physicians can choose not to enroll during the study identification period. Thus, the program is voluntary for both medical providers and patients. The unobservable factors could influence patients or their care providers not to focus on diabetes and therefore not enroll in the P4P program. We assumed that all characteristics related to health outcomes in the P4P program were captured by the measured variables among P4P and non-P4P cancer survivors, and we used a statistical PSM approach by controlling for confounding covariates (e.g. demographic characteristics, comorbid conditions, baseline density of diabetes and cancer care and time since cancer diagnosis) to avoid potential selection bias. However, caution is necessary when interpreting the effect of the P4P program on mortality. Future study may be warranted to investigate the potential benefits of comprehensive care on mortality among cancer survivors. Fifth, given our study design, we observed mortality events only over the 5-year study period. A greater effect might be found with a longer observation period. Nevertheless, our 5-year observation period is considered adequate to evaluate and compare quality improvement interventions [30] . Finally, our data were obtained from cancer survivors with diabetes in Taiwan, so results may not generalize to other P4P programs in other countries.
Conclusion
Despite these limitations, this study addressed the important issue of non-cancer care in cancer survivors with comorbid diabetes. Compared with diabetic cancer survivors who did not enroll in the P4P program, P4P survivors had lower risk of all-cause and diabetes-related mortality. Our empirical findings provide evidence of the potential benefit of diabetes P4P programs in reducing risks of competing causes of death due to diabetes or cardiovascular diseases among cancer survivors.
